Biological agents targeting IL-23 and IL-17A have shown excellent efficacy in treating psoriasis, implying that the IL-23/IL-17A axis is a major pathway involved in the pathogenesis of psoriasis (13, 14). This evidence concerns the gene IL37 and psoriasis.